3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
5
Phase 2
4
Phase 3
3
Phase 1/2
3
Status
Terminated
2
Completed
2
Sponsor Class
INDUSTRY
4
OTHER
3
Study Type
Interventional
4
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Advanced Cancer
2
Urinary Bladder Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Advanced Gastric Cancer
1
Interventions
Carboplatin
273
Paclitaxel
267
Gemcitabine
244
Bevacizumab
226
Cisplatin
218
pembrolizumab
214
Docetaxel
210
Pemetrexed
162
Capecitabine
148
Fluorouracil
129
Oxaliplatin
121
Cyclophosphamide
121
Nivolumab
112
Dexamethasone
100
Trastuzumab
89
Leucovorin
87
Cetuximab
85
Rituximab
83
Irinotecan
82
Injections
81
Erlotinib Hydrochloride
70
Prednisone
68
Doxorubicin
68
Temozolomide
67
atezolizumab
65
Bortezomib
65
Ipilimumab
64
Fulvestrant
59
Radiotherapy
54
Drug Therapy
51
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 2
×
INDUSTRY
×
linrodostat
×
Clear all
NCT02935634
2023-06-09
FRACTION-GC
Bristol-Myers Squibb
Phase 2
Completed
190 enrolled
25 charts
NCT03519256
2023-06-01
CheckMate 9UT
Bristol-Myers Squibb
Phase 2
Terminated
142 enrolled
20 charts
NCT02996110
2022-12-19
FRACTION-RCC
Bristol-Myers Squibb
Phase 2
Completed
182 enrolled
23 charts
NCT02750514
2021-03-22
FRACTION-Lung
Bristol-Myers Squibb
Phase 2
Terminated
295 enrolled
21 charts